Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus.

Autor: Ken-Opurum J; Axtria Inc., Berkeley Heights, NJ, USA. jennifer.kenopurum@axtria.com., Srinivas SSS; Axtria India Pvt. Ltd, Hyderabad, India., Jain D; Axtria India Pvt. Ltd, Noida, India., Shah T; Axtria India Pvt. Ltd, Noida, India., Samnaliev M; Axtria Inc., Berkeley Heights, NJ, USA., Dex T; Sanofi, Bridgewater, NJ, USA., Charland S; Sanofi US, Golden, CO, USA., Revel A; Sanofi, Bridgewater, NJ, USA., Preblick R; Sanofi, Bridgewater, NJ, USA.
Jazyk: angličtina
Zdroj: Diabetes therapy : research, treatment and education of diabetes and related disorders [Diabetes Ther] 2023 Dec; Vol. 14 (12), pp. 2109-2125. Date of Electronic Publication: 2023 Oct 06.
DOI: 10.1007/s13300-023-01477-3
Abstrakt: Introduction: The clinical benefits of treating patients with type 2 diabetes mellitus (T2DM) with fixed-ratio combination of insulin iGlar (iGlar) plus lixisenatide (iGlarLixi) were demonstrated in clinical trials and real-world evidence studies; however, its cost impact to healthcare payers is unknown.
Methods: A budget impact model was developed from a United States (US) payer's perspective for a hypothetical healthcare plan of 1 million people over a 1-year time horizon. In scenario analysis, patients with uncontrolled glycated hemoglobin (HbA1c) treated with 60 units or less of daily insulin (insulin cohort) or oral antidiabetic drugs (OADs) only (OAD cohort) were intensified to iGlarLixi/rapid-acting insulin (RAI)/glucagon-like peptide 1 receptor agonists (GLP-1RA) or iGlarLixi/iGlar/GLP-1RA, respectively. Model inputs from real-world data (RWD) included baseline market shares, proportion of patients intensifying to respective treatments, and dosing inputs; unit costs were obtained from published literature. One-way sensitivity analyses assessed the impact of individual parameters.
Results: Intensification with iGlarLixi resulted in the lowest incremental per member per month (PMPM) budget impact compared to other intensifying drugs (iGlar, RAI, and GLP-1RA). In the insulin cohort, the incremental PMPM cost for intensification with iGlarLixi ($0.03) was the lowest among intensifying drugs; GLP-1RA ($72.20) and RAI ($4.81). Similarly, the incremental PMPM cost for intensification with iGlarLixi was the lowest ($1.25) in the OAD cohort among intensifying drugs; GLP-1RA ($321.65) and iGlar ($114.82). In scenario analyses, when equal market intensification shares for iGlarLixi and GLP-1RA were explored, the incremental PMPM cost for iGlarLixi ($0.03) remained lower than GLP-1RA ($2.28) and RAI ($10.44) in the insulin cohort.
Conclusions: Intensification with iGlarLixi was associated with lower costs compared to other treatment intensifications, as well as overall budget reductions compared to pre-intensification when considering cost savings attributable to reduction in HbA1c; therefore, its inclusion for the treatment of T2DM would represent a budget saving.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje